[go: up one dir, main page]

WO2011039629A3 - Fracción bioactiva de petiveria alliacea, composición farmacéutica que la contiene y combinación con agentes inmunoestimulantes para el tratamiento del cáncer - Google Patents

Fracción bioactiva de petiveria alliacea, composición farmacéutica que la contiene y combinación con agentes inmunoestimulantes para el tratamiento del cáncer Download PDF

Info

Publication number
WO2011039629A3
WO2011039629A3 PCT/IB2010/002504 IB2010002504W WO2011039629A3 WO 2011039629 A3 WO2011039629 A3 WO 2011039629A3 IB 2010002504 W IB2010002504 W IB 2010002504W WO 2011039629 A3 WO2011039629 A3 WO 2011039629A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating cancer
bioactive fraction
composition containing
immunostimulants
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/002504
Other languages
English (en)
French (fr)
Other versions
WO2011039629A2 (es
Inventor
Susana Fiorentino Gomez
Maria Claudia Cifuentes Barreto
John Fredy HERNANDEZ MONTAÑO
Sandra Paola Santander Gonzalez
Claudia Patricia URUEÑA PINZON
Diana Mercedes CASTAÑEDA UVAJOA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pontificia Universidad Javeriana
Original Assignee
Pontificia Universidad Javeriana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Javeriana filed Critical Pontificia Universidad Javeriana
Priority to US13/499,798 priority Critical patent/US8734863B2/en
Priority to ES10819989T priority patent/ES2714386T3/es
Priority to CA2776446A priority patent/CA2776446C/en
Priority to BR112012009362-2A priority patent/BR112012009362B1/pt
Priority to EP10819989.4A priority patent/EP2522356B1/en
Publication of WO2011039629A2 publication Critical patent/WO2011039629A2/es
Publication of WO2011039629A3 publication Critical patent/WO2011039629A3/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está relacionada con una fracción bioactiva de Petivería alliacea con actividad antitumoral y el uso de Ia misma para Ia fabricación de medicamentos para el tratamiento del cáncer. Adicionalmente, Ia solicitud incluye una combinación farmacéutica para el tratamiento del cáncer que comprende Ia fracción bioactiva de Petiveria alliacea y al menos un agente inmunoestimulante capaz de producir Ia maduración fenotípica y/o funcional de las células dendríticas. Asimismo, se incluye un método para el tratamiento del cáncer que comprende Ia administración secuencial de Ia fracción bioactiva de Petiveria alliacea o de Ia composición que Ia contiene y un agente inmunoestimulante.
PCT/IB2010/002504 2009-10-02 2010-09-22 Fracción bioactiva de petiveria alliacea, composición farmacéutica que la contiene y combinación con agentes inmunoestimulantes para el tratamiento del cáncer Ceased WO2011039629A2 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/499,798 US8734863B2 (en) 2009-10-02 2010-09-22 Bioactive fraction of Petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer
ES10819989T ES2714386T3 (es) 2009-10-02 2010-09-22 Fracción bioactiva de Petiveria alliacea, composición farmacéutica que la contiene y combinación con agentes inmunoestimulantes para el tratamiento del cáncer
CA2776446A CA2776446C (en) 2009-10-02 2010-09-22 Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer
BR112012009362-2A BR112012009362B1 (pt) 2009-10-02 2010-09-22 Composição farmacêutica por via oral do tipo cápsula para o tratamento do câncer
EP10819989.4A EP2522356B1 (en) 2009-10-02 2010-09-22 Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CO09108636A CO6270030A1 (es) 2009-10-02 2009-10-02 Fraccion bioactiva de petivera alliacea composicion farmaceutica que la contiene y combinacion con agentes inmunoestimulantes para el tratamiento de cancer
CO09-108636 2009-10-02

Publications (2)

Publication Number Publication Date
WO2011039629A2 WO2011039629A2 (es) 2011-04-07
WO2011039629A3 true WO2011039629A3 (es) 2011-07-14

Family

ID=43826718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/002504 Ceased WO2011039629A2 (es) 2009-10-02 2010-09-22 Fracción bioactiva de petiveria alliacea, composición farmacéutica que la contiene y combinación con agentes inmunoestimulantes para el tratamiento del cáncer

Country Status (6)

Country Link
US (1) US8734863B2 (es)
EP (1) EP2522356B1 (es)
CA (1) CA2776446C (es)
CO (1) CO6270030A1 (es)
ES (1) ES2714386T3 (es)
WO (1) WO2011039629A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103549386B (zh) * 2013-10-24 2015-09-16 江苏神华药业有限公司 一种复方虫草灵芝组合物及其制备方法
US9572847B2 (en) * 2013-12-23 2017-02-21 Kingland Property Corporation, Ltd. Method for treating a lung tumor in a subject in need thereof
DK3116519T3 (da) 2014-03-13 2019-08-05 Procare Health Iberia S L Topikale sammensætninger omfattende ekstrakt fra coriolus versicolor til autoimmunitetsforbedring
CN105974042A (zh) * 2016-07-20 2016-09-28 黑龙江省电力科学研究院 一种测定绝缘油中二苄基二硫醚含量的反向高效液相色谱方法
US11779620B2 (en) * 2020-04-03 2023-10-10 Turtle Bear Holdings, Llc Combined fungal composition for modulating inflammatory response
CN119632039B (zh) * 2025-02-18 2025-06-17 天津天开瑞来有限公司 一种有机联三硫化合物在促进植物生长方面的应用和一种植物生长促进剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118874A2 (en) * 2007-03-23 2008-10-02 Qualcomm Incorporated Multi-sensor data collection and/or processing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US564830A (en) 1896-07-28 Sprocket-chain and wheel
CN1997278B (zh) * 2004-04-20 2014-04-23 艾森生物(杭州)有限公司 有取代的有机硫化合物及其使用方法
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
US8231913B2 (en) * 2005-11-10 2012-07-31 Jose Angel Olalde Rangel Angina pectoris and ischemic heart disease and synergistic phytoceutical composition for same
US7604823B2 (en) * 2006-09-07 2009-10-20 Jose Angel Olalde Rangel Synergistic HIV/AIDS and/or immune disease phyto-nutraceutical composition
US9662303B2 (en) * 2006-09-15 2017-05-30 Pg-Pharma, Llc Composition and method for treating cancer
US7390512B2 (en) * 2006-09-29 2008-06-24 Jose Angel Olalde Rangel Multiple sclerosis synergistic phyto-nutraceutical composition
US7553501B2 (en) * 2006-11-16 2009-06-30 Jose Angel Olalde Rangel Immune phyto-neutraceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118874A2 (en) * 2007-03-23 2008-10-02 Qualcomm Incorporated Multi-sensor data collection and/or processing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ROSSI V ET AL.: "Antiproliferative effects of Petiveria alliacea on sesveral tumor cell lines", PHARMACOLOGICAL RESEARCH, vol. 22, September 1990 (1990-09-01), pages 434 *
SANTANDER S.P. ET AL.: "Influencia del tratamiento de Petiveria alliacea en la expresion diferencial de genes en celulas tumorales", vol. 50, no. 3, July 2009 (2009-07-01), pages 284 - 296, ISSN: 0041-9095, Retrieved from the Internet <URL:http://med.javeriana.edu.co/publi/vniversitas/serial/v50n3/2-INFLUENCIA.pdf> [retrieved on 20110411] *
URUENA C. ET AL.: "Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells", BIOMED CENTRAL. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 8, no. 1, 18 November 2008 (2008-11-18), pages 60, XP021049619, doi:10.1186/1472-6882-8-60 *

Also Published As

Publication number Publication date
CA2776446C (en) 2020-04-07
EP2522356A2 (en) 2012-11-14
US20120294897A1 (en) 2012-11-22
US8734863B2 (en) 2014-05-27
CO6270030A1 (es) 2011-04-20
EP2522356A4 (en) 2013-05-29
BR112012009362A2 (pt) 2016-06-07
WO2011039629A2 (es) 2011-04-07
CA2776446A1 (en) 2011-04-07
EP2522356B1 (en) 2018-12-05
ES2714386T3 (es) 2019-05-28

Similar Documents

Publication Publication Date Title
EP4327867A3 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
WO2011041462A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
MY173299A (en) Method for preparing an enriched igg composition from plasma
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
MX2015007888A (es) Compuestos antivirales.
WO2011041694A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2012174158A3 (en) Administration of benzodiazepine
WO2011143201A3 (en) Ratiometric combinatorial drug delivery
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MY158195A (en) Activation of innate and adaptive immune responses by a ginseng extract
WO2011039629A3 (es) Fracción bioactiva de petiveria alliacea, composición farmacéutica que la contiene y combinación con agentes inmunoestimulantes para el tratamiento del cáncer
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
WO2011076208A3 (en) Calcipotriol monohydrate nanocrystals
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2009138507A3 (en) Anti-cancer combination therapy
WO2007089688A3 (en) Na/k-atpase ligand
WO2010150098A3 (en) Use of quingolide in the treatment of endometriosis, pain and cancer

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10819989

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010819989

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2776446

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13499798

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012009362

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012009362

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120402